To achieve true healthcare reform, we must address the high cost of prescription drugs, bring manufacturing back to the United States, expand telemedicine with equitable reimbursement rates, and promote Health Savings Accounts to reduce out-of-pocket expenses. Transparency in healthcare and prescription drug markets, along with ending surprise billing, are essential steps.
Expand access to quality, affordable health care by promoting patient-provider centered reforms, telemedicine, Health Savings Accounts, prescription drug transparency, and ending surprise billing.
Occurrences
Evidence
During the lookback window, Rules listed a Murphy-Davis-Wittman bipartisan amendment directing VA to run an HBOT pilot for veterans with traumatic brain injury or PTSD through eligible health care providers.
Roll Call 191 shows H.R.6047 passed on May 21, 2026, and lists Wittman, Republican, Virginia, as voting Yea.
Wittman said Congress, with his support, established a $50 billion Rural Health Transformation Program; he also cited support for telehealth, Health Savings Accounts, and Direct Primary Care arrangements.
Congress.gov summarizes H.R.1 as expanding HSA eligibility, including allowing HSA contributions when an HDHP provides telehealth and remote-care services before the deductible.
House Roll Call Vote 145 records H.R.1 passing 215-214, with Wittman, Robert J. listed among Yea votes.
CMS states that, as of January 1, 2022, consumers have new billing protections for emergency care, certain out-of-network care at in-network facilities, and air ambulance services.
The Congressional Record shows the House adopted the H.R.133 divided question, Roll No. 251, and lists Wittman among the Yeas.
House Roll Call Vote 708 records H.R.5378 passing 320-71 and lists Wittman, Robert J. as Yea.
Assessments
Wittman has concrete same-term federal actions tied to parts of the promise: he voted for H.R.1 provisions expanding HSA eligibility and telehealth/remote-care treatment, supported veterans health access legislation and an HBOT pilot amendment, and previously voted for the appropriations vehicle that enacted the No Surprises Act. However, the evidence does not show full delivery of the broader commitment across affordable health care, patient-provider centered reforms, prescription drug transparency, and all access goals; some transparency work only passed the House and did not become law. This supports partial fulfillment with meaningful effort, not full delivery.